

TRIZOL IN


- ✓ No phase separation
- ✓ No precipitation
- ✓ No RNA loss



RNA OUT


7 minutes from TRIZOL® to RNA:
Mix sample in TRIZOL®, TRI Reagent®, or similar.
Add ethanol & load into the Zymo-Spin™ column.
Patented technology

High-quality small & large RNA




High-quality small and large RNAs are effectively recovered using the Direct-zol™ kit. RNA is DNA-free.

Non-biased miRNA recovery



The data show RNA purified from TRIZOL samples using the Direct-zol™ RNA MiniPrep compared to an unbiased method (mirVana®, Ambion). Micro-RNA analysis was performed using miRNA-Seq (MiSeq®, Illumina) and a direct hybridization assay (nCounter®, Nanostring).

Highly cited



Samples available at zymoresearch.com/direct-zol or call (949) 679-1190

Product	Cat. No.	Size
Direct-zol™ RNA MicroPrep	R2060, R2061* R2062, R2063*	50 Preps. (≤10 µg RNA) 200 Preps. (≤10 µg RNA)
Direct-zol™ RNA MiniPrep	R2050, R2051* R2052, R2053*	50 Preps. (≤50 µg RNA) 200 Preps. (≤50 µg RNA)
Direct-zol™ RNA MiniPrep Plus	R2070, R2071* R2072, R2073*	50 Preps. (≤100 µg RNA) 200 Preps. (≤100 µg RNA)

96-well spin plate & MagBead formats also available

* = Supplied with TRI Reagent®

Extraordinary variation of floral organs in *Phalaenopsis* orchid is due to differential expression of multiple genes in sepal, petal, and labellum.¹

¹ Hsiao, Y. et al. *Gene*. 518, 91-100 (2013).

Differential gene expression creates beauty

Differential gene expression plays a significant role in development of many species including orchids.

Phalaenopsis orchids are important species for development and evolutionary studies. Moreover, they are well recognized for their exceptional beauty. The flowers have several organs (i.e. sepal, petal, and labellum), which are significantly different, however together compose conspicuous and harmonious look (view photo). The unique shape of these flower organs is a result of differential expression of multiple genes involved in their development.

Lexogen is focusing on development of accurate and affordable tools for transcriptome analysis with RNA-Seq. QuantSeq is a dedicated kit for expression profiling. It is an easy protocol for producing highly strand-specific next generation sequencing libraries from the 3' end of polyadenylated RNA. Only one fragment per transcript is produced, directly linking the number of mapping reads to the gene expression values. Restricted length saves sequencing space and allows for high level of multiplexing, enabling cost-efficient and fast RNA-Seq experiment.



Expression Profiling RNA-Seq Library Prep Kit

- Gene expression analysis
- Exact 3' UTR tagging
- From 100 pg total RNA input including low quality RNA and FFPE samples
- Cost-effective sequencing of up to 96 samples / lane
- Ready-to-sequence libraries in 4.5 hours
- Illumina™ and Ion Torrent™ compatible
- Reduced data analysis time
- Custom solutions available

LEXOGEN
Enabling complete transcriptome sequencing

www.lexogen.com

Break free from qPCR

Find gene targets faster



Validating gene targets with qPCR is often slow and costly due to lengthy primer design, experimental assay optimization, and sample processing time.

QuantiGene® Plex Assays validate gene targets faster:

- No RNA purification or reverse transcription is required
- Multiplex panels of up to 80 genes are functionally validated
- One QuantiGene Plex® plate provides as much information as 20 qPCR plates

Fast-track your discovery at www.ebioscience.com/breakfree

Biology for a better world.

NORTH AMERICA: 888-999-1371 ■ EUROPE: +43 1 796 40 40-305 ■ JAPAN: +81 (0)3 6430 4020 ■ INQUIRIES: info@ebioscience.com

© 2016 Affymetrix, Inc. All rights reserved. For Research Use Only. Not for use in diagnostic or therapeutic procedures.

JUST RIGHT FOR...

AUTOMATION FOR THE COMPLETE LINEUP OF GENOMIC APPLICATIONS.

For any throughput—and any application—the Fragment Analyzer™ is the premier instrument for simultaneously automating the qualification and quantification of nucleic acid fragments and smears.



More at AATI-US.COM



With our biofluid sequencing experts,
you're in safe hands

Looking for non-invasive biomarkers?

With years of experience profiling microRNAs in liquid biopsies, our team of biofluid experts know how to ensure top quality microRNA sequencing data with high mapping percentages – even from clinical serum/plasma samples.

Everything we do is designed to advance your project and maximize discovery from your biofluid samples – from high quality RNA isolation to comprehensive data analysis.

You can trust us with your valuable clinical biofluid samples.

We pioneered microRNA analysis in biofluids.

Sequence microRNA in
clinical serum/plasma samples




Biofluids microRNA NGS Services

exiqon.com/biofluids-ngs

www.exiqon.com

EXIQON
Seek Find Verify



An AACR Special Conference on

TUMOR IMMUNOLOGY AND IMMUNOTHERAPY

October 20-23, 2016 • Boston Marriott Copley Place • Boston, MA

Submit an Abstract By: Monday, July 18, 2016

Register and Save By: Friday, September 9, 2016

CONFERENCE CO-CHAIRPERSONS



James P. Allison

The University of Texas MD Anderson
Cancer Center, Houston, TX



Pamela S. Ohashi

Princess Margaret Cancer Centre,
Toronto, ON, Canada



Antoni Ribas

UCLA Medical Center, Los Angeles, CA



Ton Schumacher

Netherlands Cancer Institute,
Amsterdam, The Netherlands

ABOUT THIS CONFERENCE

A hallmark of this AACR immunology series is the integration of several sub-disciplines of cancer immunology and immunotherapy, with a broad focus on strategies to harness the immune system for the treatment and prevention of different cancers. Leaders in the field will present their latest work and provide critical updates on our deepening understanding of the immune response towards cancer. This Special Conference will also provide a unique opportunity for the authors of highly rated abstracts to present their work to an audience of researchers from around the world. Ample time will be provided for the stimulating discussions that are necessary to further the scientific and translational goals of the field. As the sixth in the series, this conference will continue to provide a forum for the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists—from academia to industry.



Continuing Medical Education (CME) Activity—AMA PRA Category 1 Credits™ available

Learn more and register at
AACR.org/TII16

#AACRTII16

AACR American Association
for Cancer Research

FINDING CURES TOGETHERSM

Next Generation Sequencing (NGS) Services

SBS Genetech provides a wide variety of next generation sequencing suitable for most research needs. We offer comprehensive services including library preparation, sample validation, sequencing, and bioinformatics.

- **Comprehensive NGS Services**


- Genomic DNA Sequencing
- Strand Specific RNA Sequencing
- miRNA Sequencing
- PCR Amplicon Sequencing
- 16S Metagenomic Sequencing

- **Sequencing Only Services**


- HiSeq Sequencing
- MiSeq Sequencing

- **Specialized Sequencing Services**

- Library Generation
- Project Planning and Consultation



Interested? Please send your inquiries to order@sbsbio.com



2016-2017 SCIENTIFIC CONFERENCES

Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment

EORTC-NCI-EMA-AACR International Conference on Innovation and Biomarkers in Cancer Drug Development

Conference Co-Chairpersons:
Denis A. Lacombe and John W. Martens
September 8-9, 2016 • Brussels, Belgium

11th Biennial Ovarian Cancer Research Symposium

Conference Co-Chairpersons: *Deborah K. Armstrong, Martin M. Matzuk, Gordon B. Mills, and Saul E. Rivkin*
September 12-13, 2016 • Seattle, WA
Co-presented with the Rivkin Center for Ovarian Cancer

Colorectal Cancer: From Initiation to Outcomes

Conference Co-Chairpersons: *Ernest T. Hawk, Steven H. Itzkowitz, Kenneth W. Kinzler, and Johanna W. Lampe*
September 17-20, 2016 • Tampa, FL

Ninth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved

Conference Co-Chairpersons: *Rick A. Kittles, Folakemi T. Odedina, Jeffrey N. Weitzel, and Jun J. Yang*
September 25-28, 2016 • Fort Lauderdale, FL

CRI-CIMT-EATI-AACR Second International Cancer Immunotherapy Conference: Translating Science into Survival

Conference Co-Chairpersons: *James P. Allison, Philip D. Greenberg, Christoph Huber, and Guido Kroemer*
September 25-28, 2016 • New York, NY

Tumor Immunology and Immunotherapy

Conference Co-Chairpersons: *James P. Allison, Pamela S. Ohashi, Antoni Ribas, and Ton Schumacher*
October 20-23, 2016 • Boston, MA

Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy

Conference Co-Chairpersons: *Jennifer A. Doudna, Frank McCormick, Davide Ruggero, and Nahum Sonenberg*
October 27-30, 2016 • San Francisco, CA

DNA Repair: Tumor Development and Therapeutic Response

Conference Co-Chairpersons: *Robert G. Bristow, Maria Jasin, and Theodore S. Lawrence*
November 2-5, 2016 • Montreal, Quebec, Canada

New Horizons in Cancer Research: Delivering Cures Through Cancer Science

Conference Co-Chairpersons: *José Baselga and Scott A. Armstrong*
November 2-5, 2016 • Shanghai, P.R. China

Improving Cancer Risk Prediction for Prevention and Early Detection

Conference Co-Chairpersons: *Graham A. Coditz, Susan M. Gapstur, Kenneth R. Muir, and Mark E. Sherman*
November 16-19, 2016 • Orlando, FL

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Conference Co-Chairpersons: *Jean-Charles Soria, Lee J. Helman, and Levi A. Garraway*
November 29-December 2, 2016 • Munich, Germany

San Antonio Breast Cancer Symposium

Symposium Co-Directors: *Carlos L. Arteaga, Virginia G. Kaklamani, and C. Kent Osborne*
December 6-10, 2016 • San Antonio, TX

Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer

Conference Co-Chairpersons: *René Bernards, William C. Hahn, and Louis M. Staudt*
January 4-7, 2017 • San Diego, CA

AACR International Conference on New Frontiers in Cancer Research

Conference Co-Chairpersons: *Peter A. Jones and Frank McCormick*
January 18-22, 2017 • Cape Town, South Africa

AACR Annual Meeting 2017

Program Committee Chairperson: *Kornelia Polyak*
April 1-5, 2017 • Washington, DC

Learn more and register at
AACR.org/Calendar

AACR American Association
for Cancer Research

FINDING CURES TOGETHER™

Announcing Keystone Symposia's 2016–2017 RNA Conferences

Precision Genome Engineering

Scientific Organizers: J. Keith Joung, Emmanuelle Charpentier and Olivier Danos

January 8–12, 2017 | Breckenridge, Colorado | USA

www.keystonesymposia.org/17A2

Deadlines: Scholarship/Discounted Abstract – Sep 13, 2016; Abstract – Oct 6, 2016; Discounted Registration – Nov 9, 2016

Omics Strategies to Study the Proteome

Scientific Organizers: Alan Saghatelian, Chuan He and Ileana M. Cristea

January 29–February 2, 2017 | Breckenridge, Colorado | USA

www.keystonesymposia.org/17A8

Deadlines: Scholarship/Discounted Abstract – Sep 28, 2016; Abstract – Oct 27, 2016; Discounted Registration – Nov 29, 2016

Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics

Scientific Organizers: Johnathan R. Whetstone, Jessica K. Tyler and Rabinder K. Prinjha

January 29–February 2, 2017 | Seattle, Washington | USA

www.keystonesymposia.org/17A9

Deadlines: Scholarship/Discounted Abstract – Sep 29, 2016; Abstract – Oct 27, 2016; Discounted Registration – Nov 30, 2016

Noncoding RNAs from Disease to Targeted Therapeutics

Scientific Organizers: Kevin V. Morris, Archa Fox and Paloma Hoban Giangrande

joint with **Protein-RNA Interactions: Scale, Mechanisms, Structure and Function of Coding and Noncoding RNPs**

Scientific Organizers: Gene W. Yeo, Jernej Ule, Karla Neugebauer and Melissa J. Moore

February 5–9, 2017 | Banff, Alberta | Canada

www.keystonesymposia.org/17J5 | www.keystonesymposia.org/17J6

Deadlines: Scholarship/Discounted Abstract – Oct 5, 2016; Abstract – Nov 2, 2016; Discounted Registration – Dec 6, 2016

mRNA Processing and Human Disease

Scientific Organizers: James L. Manley, Siddhartha Mukherjee and Gideon Dreyfuss

March 5–8, 2017 | Taos, New Mexico | USA

www.keystonesymposia.org/17C3

Deadlines: Scholarship/Discounted Abstract – Nov 2, 2016; Abstract – Dec 6, 2016; Discounted Registration – Jan 10, 2017

RNA-Based Approaches in Cardiovascular Disease

Scientific Organizers: Thomas Thum and Roger J. Hajjar


joint with **Molecular Mechanisms of Heart Development**

Scientific Organizers: Benoit G. Bruneau, Brian L. Black and Margaret E. Buckingham

March 26–30, 2017 | Keystone, Colorado | USA

www.keystonesymposia.org/17X8

Deadlines: Scholarship/Discounted Abstract – Nov 30, 2016; Abstract – Jan 11, 2017; Discounted Registration – Jan 26, 2017



Submit an abstract to participate fully in the conference via a poster presentation and possible selection for a short talk. Scholarships are available for graduate students and postdoctoral fellows. For full program, speaker, abstract and scholarship details, visit www.keystonesymposia.org/genetics

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery

PO Box 1630 | Silverthorne, CO 80498 | 800-253-0685 | 970-262-1230



CRISPR

Dharmacon reagents help you move forward. Faster.

Simplify your gene editing workflow with the Dharmacon™ Edit-R™ CRISPR-Cas9 platform. Custom or predesigned ready-to-use DNA and synthetic RNA leverage a validated algorithm to select highly functional, specific targets for gene knockout – enabling you to quickly assess multiple target sites per gene across one or hundreds of genes.

CRISPR Guide RNAs | CRISPR Screening Libraries | Cas9 Nucleases

crRNAs that have high functionality scores show high editing efficiency



HEK293T-CAG-Cas9 cells were transfected with either high-scoring or low-scoring crRNAs (50 nM crRNA:tracrRNA) using DharmaFECT 1 transfection reagent (0.25 μ L/well) in 96-well format. Gene editing efficiencies were determined using next-generation sequencing. 93% of the top 10 high-scoring crRNAs targeting ten different genes have > 40% indel formation and only 33% of the 10 lowest scoring designs have > 40% indel formation.





Targeting the Pathways of Human DiseaseSM with microRNA Therapeutics

A single *microRNA* can target and regulate up to hundreds of genes. These genes are in turn integrally involved in biological networks and pathways, including disease states. Targeting pathways of human disease with *microRNA*-based drugs represents a potentially powerful therapeutic approach.



 **REGULUS**
THERAPEUTICS™
regulusrx.com